CN112996795B - 作为src同源-2磷酸酶抑制剂的稠合的三环衍生物 - Google Patents
作为src同源-2磷酸酶抑制剂的稠合的三环衍生物 Download PDFInfo
- Publication number
- CN112996795B CN112996795B CN201980074211.0A CN201980074211A CN112996795B CN 112996795 B CN112996795 B CN 112996795B CN 201980074211 A CN201980074211 A CN 201980074211A CN 112996795 B CN112996795 B CN 112996795B
- Authority
- CN
- China
- Prior art keywords
- compound
- alkyl
- pharmaceutically acceptable
- acceptable salt
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862733061P | 2018-09-18 | 2018-09-18 | |
| US62/733,061 | 2018-09-18 | ||
| US201862749655P | 2018-10-23 | 2018-10-23 | |
| US62/749,655 | 2018-10-23 | ||
| US201962810911P | 2019-02-26 | 2019-02-26 | |
| US62/810,911 | 2019-02-26 | ||
| US201962883121P | 2019-08-06 | 2019-08-06 | |
| US201962883120P | 2019-08-06 | 2019-08-06 | |
| US62/883,120 | 2019-08-06 | ||
| US62/883,121 | 2019-08-06 | ||
| PCT/US2019/051592 WO2020061103A1 (en) | 2018-09-18 | 2019-09-17 | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112996795A CN112996795A (zh) | 2021-06-18 |
| CN112996795B true CN112996795B (zh) | 2024-11-12 |
Family
ID=68084982
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980074211.0A Active CN112996795B (zh) | 2018-09-18 | 2019-09-17 | 作为src同源-2磷酸酶抑制剂的稠合的三环衍生物 |
| CN201980074583.3A Active CN113227103B (zh) | 2018-09-18 | 2019-09-17 | 作为src同源-2磷酸酶抑制剂的三取代的杂芳基衍生物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980074583.3A Active CN113227103B (zh) | 2018-09-18 | 2019-09-17 | 作为src同源-2磷酸酶抑制剂的三取代的杂芳基衍生物 |
Country Status (22)
| Country | Link |
|---|---|
| US (6) | US11459340B2 (https=) |
| EP (2) | EP3853233A1 (https=) |
| JP (2) | JP7542538B2 (https=) |
| KR (2) | KR102834408B1 (https=) |
| CN (2) | CN112996795B (https=) |
| AU (2) | AU2019344899B2 (https=) |
| BR (1) | BR112021005082A2 (https=) |
| CA (2) | CA3113233A1 (https=) |
| CL (1) | CL2021000628A1 (https=) |
| CO (1) | CO2021004436A2 (https=) |
| CR (1) | CR20210175A (https=) |
| DK (1) | DK3853234T3 (https=) |
| ES (1) | ES3036496T3 (https=) |
| FI (1) | FI3853234T3 (https=) |
| MX (1) | MX2021003158A (https=) |
| PH (1) | PH12021550604A1 (https=) |
| PL (1) | PL3853234T3 (https=) |
| PT (1) | PT3853234T (https=) |
| SA (1) | SA521421505B1 (https=) |
| SG (1) | SG11202102679QA (https=) |
| TW (1) | TWI827677B (https=) |
| WO (2) | WO2020061103A1 (https=) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102598895B1 (ko) | 2016-07-12 | 2023-11-07 | 레볼루션 메디슨즈, 인크. | 다른자리 입체성 shp2 억제제로서의 2,5-이치환 3-메틸 피라진 및 2,5,6-3치환 3-메틸 피라진 |
| US11529347B2 (en) | 2016-09-22 | 2022-12-20 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of use thereof |
| TW202500565A (zh) | 2016-10-24 | 2025-01-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| MX2019008695A (es) | 2017-01-23 | 2019-09-11 | Revolution Medicines Inc | Compuestos biciclicos como inhibidores alostericos de shp2. |
| MX2019008696A (es) | 2017-01-23 | 2019-09-13 | Revolution Medicines Inc | Compuestos de piridina como inhibidores de shp2 alostericos. |
| WO2018218133A1 (en) | 2017-05-26 | 2018-11-29 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| EP3687997A1 (en) | 2017-09-29 | 2020-08-05 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| MX2020003579A (es) * | 2017-10-12 | 2020-07-22 | Revolution Medicines Inc | Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos. |
| BR112020009757A2 (pt) | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | compostos policíclicos como inibidores alostéricos de shp2 |
| SG11202009245TA (en) | 2018-03-21 | 2020-10-29 | Relay Therapeutics Inc | Shp2 phosphatase inhibitors and methods of use thereof |
| WO2019183364A1 (en) | 2018-03-21 | 2019-09-26 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof |
| JP7542538B2 (ja) | 2018-09-18 | 2024-08-30 | ニカング セラピューティクス， インコーポレイテッド | Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての縮合三環式環誘導体 |
| WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
| CN113365988B (zh) * | 2019-01-31 | 2023-10-03 | 贝达药业股份有限公司 | Shp2抑制剂及其应用 |
| CN114127053B (zh) * | 2019-09-06 | 2023-06-13 | 四川科伦博泰生物医药股份有限公司 | 一种取代吡嗪化合物、其制备方法和用途 |
| US20230010886A1 (en) * | 2019-09-23 | 2023-01-12 | Suzhou Puhe BioPharma Co., Ltd. | Shp2 inhibitors and uses thereof |
| AU2020354475A1 (en) | 2019-09-24 | 2022-05-05 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of making and using the same |
| TW202128688A (zh) | 2019-11-08 | 2021-08-01 | 美商銳新醫藥公司 | 雙環雜芳基化合物及其用途 |
| EP4076667A1 (en) | 2019-12-20 | 2022-10-26 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| IL299131A (en) | 2020-06-18 | 2023-02-01 | Revolution Medicines Inc | Methods for delaying, preventing and treating acquired resistance to RAS inhibitors |
| EP4169913A4 (en) * | 2020-06-22 | 2024-10-30 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | SUBSTITUTED PYRAZINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF |
| CN116113418A (zh) * | 2020-08-25 | 2023-05-12 | 四川科伦博泰生物医药股份有限公司 | 杂环化合物及其制备方法和用途 |
| MX2023002248A (es) | 2020-09-03 | 2023-05-16 | Revolution Medicines Inc | Uso de inhibidores de sos1 para tratar neoplasias malignas con mutaciones de shp2. |
| MX2023003060A (es) | 2020-09-15 | 2023-04-05 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer. |
| AU2021347232A1 (en) | 2020-09-23 | 2023-04-27 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| JP2023553532A (ja) * | 2020-12-11 | 2023-12-21 | エラスカ，インク． | 癌の処置のための併用療法 |
| CN117083283A (zh) * | 2020-12-11 | 2023-11-17 | 医睿世康药业研发公司 | 用于癌症治疗的联合疗法 |
| JP2023553533A (ja) * | 2020-12-11 | 2023-12-21 | エラスカ，インク． | 癌の処置のための併用療法 |
| WO2022125971A1 (en) * | 2020-12-11 | 2022-06-16 | Erasca, Inc. | Combination therapies for the treatment of cancer |
| CN117120449A (zh) * | 2020-12-11 | 2023-11-24 | 医睿世康药业研发公司 | 用于癌症治疗的联合疗法 |
| CN117098537A (zh) * | 2020-12-11 | 2023-11-21 | 医睿世康药业研发公司 | 用于癌症治疗的联合疗法 |
| WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| CA3202424A1 (en) * | 2020-12-18 | 2022-06-23 | Genzyme Corporation | Process for preparing shp2 inhibitors |
| CN116848121A (zh) * | 2020-12-18 | 2023-10-03 | 建新公司 | 制备shp2抑制剂的方法 |
| CN117083285A (zh) * | 2021-03-31 | 2023-11-17 | 南京明德新药研发有限公司 | 一系列含Se的吡嗪类化合物及其应用 |
| CA3217393A1 (en) | 2021-05-05 | 2022-11-10 | Elena S. Koltun | Ras inhibitors |
| AU2022268962A1 (en) | 2021-05-05 | 2023-12-14 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
| WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| US20240285624A1 (en) * | 2021-06-24 | 2024-08-29 | Erasca, Inc. | Erk1/2 or shp2 inhibitors and flt3 inhibitors combination therapy |
| MX2023015298A (es) * | 2021-06-24 | 2024-03-20 | Erasca Inc | Terapia de combinación de inhibidores de erk1/2 y shp2. |
| US20240293422A1 (en) * | 2021-06-24 | 2024-09-05 | Erasca, Inc. | Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer |
| CA3226206A1 (en) * | 2021-07-09 | 2023-01-12 | Kanaph Therapeutics Inc. | Shp2 inhibitor and use thereof |
| CA3224341A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
| WO2023044065A1 (en) * | 2021-09-17 | 2023-03-23 | Erasca, Inc. | Jak inhibitor with erk1/2 and/or shp2 inhibitors combination therapy |
| WO2023059771A1 (en) * | 2021-10-06 | 2023-04-13 | Erasca, Inc. | Uses of tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors |
| AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
| CN119136806A (zh) | 2022-03-08 | 2024-12-13 | 锐新医药公司 | 用于治疗免疫难治性肺癌的方法 |
| IL316768A (en) | 2022-05-25 | 2025-01-01 | Ikena Oncology Inc | MEK inhibitors and their uses |
| WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
| WO2024042361A1 (en) * | 2022-08-24 | 2024-02-29 | Sudo Biosciences Limited | Tyk2 inhibitors and uses thereof |
| TW202440128A (zh) * | 2023-01-06 | 2024-10-16 | 美商艾瑞斯卡公司 | Raf抑制劑及erk1/2及/或shp2抑制劑組合療法 |
| EP4687905A1 (en) | 2023-03-30 | 2026-02-11 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| KR20260005904A (ko) | 2023-04-07 | 2026-01-12 | 레볼루션 메디슨즈, 인크. | 매크로사이클릭 ras 억제제 |
| CN121263418A (zh) | 2023-04-07 | 2026-01-02 | 锐新医药公司 | 大环ras抑制剂 |
| KR20250172857A (ko) | 2023-04-14 | 2025-12-09 | 레볼루션 메디슨즈, 인크. | Ras 억제제의 결정형 |
| AU2024252105A1 (en) | 2023-04-14 | 2025-10-16 | Revolution Medicines, Inc. | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| AU2024265078A1 (en) | 2023-05-04 | 2025-12-11 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| IL326136A (en) | 2023-08-07 | 2026-03-01 | Revolution Medicines Inc | RMC-6291 for use in the treatment of a disease or disorder associated with the RAS protein |
| US20250154171A1 (en) | 2023-10-12 | 2025-05-15 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| US20250375445A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016203405A1 (en) * | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| WO2018013597A1 (en) * | 2016-07-12 | 2018-01-18 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
Family Cites Families (383)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6041077B2 (ja) | 1976-09-06 | 1985-09-13 | 喜徳 喜谷 | １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体 |
| US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
| JPS62135830A (ja) | 1985-12-09 | 1987-06-18 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料及びその処理方法 |
| JPS62135835A (ja) | 1985-12-09 | 1987-06-18 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料の処理方法 |
| JPS62135834A (ja) | 1985-12-09 | 1987-06-18 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料の処理方法 |
| JPS62135832A (ja) | 1985-12-09 | 1987-06-18 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料の処理方法 |
| JPS62136654A (ja) | 1985-12-10 | 1987-06-19 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料の処理方法 |
| JPS62136651A (ja) | 1985-12-10 | 1987-06-19 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー写真感光材料の処理方法 |
| JPS62136650A (ja) | 1985-12-11 | 1987-06-19 | Fuji Photo Film Co Ltd | ハロゲン化銀カラ−写真感光材料及びその処理方法 |
| JPS62206545A (ja) | 1986-03-07 | 1987-09-11 | Fuji Photo Film Co Ltd | ハロゲン化銀写真感光材料 |
| GB8729614D0 (en) | 1987-12-18 | 1988-02-03 | Beecham Group Plc | Novel compounds |
| US5266573A (en) | 1989-08-07 | 1993-11-30 | Elf Sanofi | Trifluoromethylphenyltetrahydropyridines for the treatment and/or prophylaxis of intestinal motility disorders |
| US5360459A (en) | 1991-05-13 | 1994-11-01 | The Lubrizol Corporation | Copper-containing organometallic complexes and concentrates and diesel fuels containing same |
| JPH05196976A (ja) | 1991-11-18 | 1993-08-06 | Toshiba Corp | 有機非線形光学材料 |
| JPH05181221A (ja) | 1991-12-27 | 1993-07-23 | Konica Corp | ハロゲン化銀写真感光材料 |
| GB9201755D0 (en) | 1992-01-28 | 1992-03-11 | British Bio Technology | Compounds |
| FR2687932A1 (fr) | 1992-02-27 | 1993-09-03 | Oreal | Dispersion huile-dans-l'eau susceptible de former des films composites. |
| EP0647450A1 (en) | 1993-09-09 | 1995-04-12 | BEHRINGWERKE Aktiengesellschaft | Improved prodrugs for enzyme mediated activation |
| HRP970371A2 (en) | 1996-07-13 | 1998-08-31 | Kathryn Jane Smith | Heterocyclic compounds |
| AU3785597A (en) | 1996-08-14 | 1998-03-06 | Takeda Chemical Industries Ltd. | Cyclic urea compounds, their production and use as herbicides |
| US5977134A (en) | 1996-12-05 | 1999-11-02 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| US6117973A (en) | 1997-02-24 | 2000-09-12 | Georgia Tech Research Corp. | PNA monomers with electron donor or acceptor |
| FR2761687B1 (fr) | 1997-04-08 | 2000-09-15 | Centre Nat Rech Scient | Derives de quinoleines, possedant notamment des proprietes antivirales, leurs preparations et leurs applications biologiques |
| JP2000072695A (ja) | 1998-08-24 | 2000-03-07 | Sumitomo Pharmaceut Co Ltd | 環状化合物 |
| US6465467B1 (en) | 1999-05-21 | 2002-10-15 | Biovitrum Ab | Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases |
| ES2252004T3 (es) | 1999-05-21 | 2006-05-16 | Biovitrum Ab | Nuevos compuestos, su uso y preparacion. |
| PE20010306A1 (es) | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| US6699873B1 (en) | 1999-08-04 | 2004-03-02 | Millennium Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
| MXPA02001160A (es) | 1999-08-04 | 2002-07-02 | Millennium Pharm Inc | Compuestos que se unen a los receptores para melanocortina-4, y metodo de uso de estos. |
| US6514964B1 (en) | 1999-09-27 | 2003-02-04 | Amgen Inc. | Fused cycloheptane and fused azacycloheptane compounds and their methods of use |
| ES2252063T3 (es) | 1999-09-28 | 2006-05-16 | Eisai Co., Ltd. | Compuesto de quinuclidina y medicamento que comprende el compuesto como principio activo. |
| GB0018891D0 (en) | 2000-08-01 | 2000-09-20 | Novartis Ag | Organic compounds |
| JP4548761B2 (ja) | 2000-06-15 | 2010-09-22 | 富士フイルムホールディングス株式会社 | 潤滑剤組成物 |
| WO2002000651A2 (en) | 2000-06-27 | 2002-01-03 | Bristol-Myers Squibb Pharma Company | Factor xa inhibitors |
| DE10032633A1 (de) | 2000-07-05 | 2002-01-17 | Bayer Ag | Verfahren zum Auffinden von Hemmstoffen der Protoporphyrinogen-Oxidase |
| JP2002122954A (ja) | 2000-08-08 | 2002-04-26 | Fuji Photo Film Co Ltd | 感光性ハロゲン化銀写真乳剤、これを含有するハロゲン化銀写真感光材料および感光性ハロゲン化銀写真乳剤の感度向上方法 |
| AU2001279955A1 (en) | 2000-08-18 | 2002-03-04 | Sterix Limited | 2-substituted estradiol derivative for inhibiting superoxid dismutase |
| US6963001B2 (en) | 2000-09-30 | 2005-11-08 | Henkel Corporation | Low shrinkage thermosetting resin compositions and methods of use therefor |
| WO2002028813A1 (en) | 2000-09-30 | 2002-04-11 | Loctite | Low shrinkage thermosetting resin compositions and methods of use therefor |
| EP1578341A2 (en) | 2000-10-11 | 2005-09-28 | Tularik Inc. | Modulation of ccr4 function |
| EP1217000A1 (en) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Inhibitors of factor Xa and factor VIIa |
| US6995162B2 (en) | 2001-01-12 | 2006-02-07 | Amgen Inc. | Substituted alkylamine derivatives and methods of use |
| NZ535574A (en) | 2001-01-16 | 2006-07-28 | Astrazeneca Ab | Therapeutic heterocyclic compounds |
| CN1592745A (zh) | 2001-01-16 | 2005-03-09 | 阿斯特拉曾尼卡有限公司 | 治疗用苯并－γ－吡喃酮化合物 |
| SE0103646D0 (sv) | 2001-11-01 | 2001-11-01 | Astrazeneca Ab | Therapeutic chroman compounds |
| JP3616628B2 (ja) | 2001-03-01 | 2005-02-02 | 塩野義製薬株式会社 | Ｈｉｖインテグラーゼ阻害活性を有する含窒素芳香族複素環化合物 |
| RU2003132706A (ru) | 2001-04-06 | 2005-04-20 | Байокрист Фармасьютикалз, Инк. (Us) | Диариловые соединения в качестве ингибиторов сериновых протеаз |
| WO2003003008A1 (en) | 2001-06-29 | 2003-01-09 | 7Tm Pharma A/S | Chemical libraries useful for drug discovery processes |
| WO2003003009A1 (en) | 2001-06-29 | 2003-01-09 | 7Tm Pharma A/S | Use of metal-ion chelates in validating biological molecules as drug targets in test animal models |
| JO3429B1 (ar) | 2001-08-13 | 2019-10-20 | Janssen Pharmaceutica Nv | مشتقات برميدينات مثبطة فيروس الايدز |
| FR2831536A1 (fr) | 2001-10-26 | 2003-05-02 | Aventis Pharma Sa | Nouveaux derives de benzimidazoles, leur procede de preparation, leur application a titre de medicament, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteurs de kdr |
| US6897208B2 (en) | 2001-10-26 | 2005-05-24 | Aventis Pharmaceuticals Inc. | Benzimidazoles |
| US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
| JP4547911B2 (ja) | 2002-02-01 | 2010-09-22 | アリアド・ファーマシューティカルズ・インコーポレイテッド | リン含有化合物およびその用途 |
| US7375134B2 (en) | 2002-03-05 | 2008-05-20 | Axys Pharmaceuticals, Inc. | Cathepsin cysteine protease inhibitors |
| AU2003218629A1 (en) | 2002-03-15 | 2003-09-29 | Nuevolution A/S | A building block forming a c-c or a c-hetero atom bond uponreaction |
| TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| US7183313B2 (en) | 2002-08-23 | 2007-02-27 | University Of Connecticut | Keto cannabinoids with therapeutic indications |
| US7071355B2 (en) | 2002-12-23 | 2006-07-04 | 4 Sc Ag | Compounds as anti-inflammatory, immunomodulatory and anti-proliferatory agents |
| WO2004080966A1 (ja) | 2003-03-14 | 2004-09-23 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| GB0306430D0 (en) | 2003-03-20 | 2003-04-23 | Bp Chem Int Ltd | Polymerisation and oligomerisation catalysts |
| JP4847868B2 (ja) | 2003-05-14 | 2011-12-28 | ニューロジェネティック ファーマシューティカルズ、 インコーポレイテッド | 化合物、及び、アミロイドベータの調節におけるその使用 |
| WO2004101529A1 (ja) | 2003-05-19 | 2004-11-25 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環化合物およびその医薬用途 |
| US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
| JP4231379B2 (ja) | 2003-10-15 | 2009-02-25 | 富士フイルム株式会社 | 潤滑剤組成物 |
| JP2005170939A (ja) | 2003-11-20 | 2005-06-30 | Takeda Chem Ind Ltd | 糖尿病の予防・治療剤 |
| DE10355066A1 (de) | 2003-11-25 | 2005-06-23 | Basf Ag | Verfahren zur asymmetrischen Synthese |
| US7632946B2 (en) | 2004-02-06 | 2009-12-15 | Abbott Laboratories | Naphthyridine-based antibacterial compositions |
| JP2005263787A (ja) | 2004-02-17 | 2005-09-29 | Ishihara Sangyo Kaisha Ltd | アミド系化合物又はその塩、並びにそれらを含有するサイトカイン産生抑制剤 |
| WO2005099688A2 (en) | 2004-04-07 | 2005-10-27 | Takeda Pharmaceutical Company Limited | Cyclic compounds |
| EP1595888A1 (en) | 2004-05-11 | 2005-11-16 | Degussa AG | Cycloolefin phosphine ligands and their use in catalysis |
| GB0412467D0 (en) | 2004-06-04 | 2004-07-07 | Astrazeneca Ab | Chemical compounds |
| EP1760071A4 (en) | 2004-06-23 | 2008-03-05 | Ono Pharmaceutical Co | COMPOUND WITH S1P RECEPTOR BINDING ABILITY AND USE THEREOF |
| GB0415879D0 (en) | 2004-07-15 | 2004-08-18 | Bp Chem Int Ltd | Polymerisation catalyst |
| GB0418022D0 (en) | 2004-08-12 | 2004-09-15 | Bp Chem Int Ltd | Polymerisation and oligomerisation catalyst |
| DK1789390T3 (da) | 2004-09-02 | 2012-02-27 | Genentech Inc | Pyridyl-inhibitorer af hedgehog-signalering |
| GB0420396D0 (en) | 2004-09-14 | 2004-10-13 | Bp Chem Int Ltd | Polyolefins |
| WO2006038594A1 (ja) | 2004-10-04 | 2006-04-13 | Ono Pharmaceutical Co., Ltd. | Ｎ型カルシウムチャネル阻害薬 |
| GB2436261B (en) | 2004-12-11 | 2010-06-09 | Merck Patent Gmbh | Liquid crystal compounds,liquid crystal medium and liquid crystal display |
| JP2008527030A (ja) | 2005-01-19 | 2008-07-24 | バイオリポックス エービー | 炎症の治療に有用なインドール類 |
| JP4749000B2 (ja) | 2005-02-22 | 2011-08-17 | 富士フイルム株式会社 | グリース組成物 |
| US20070135437A1 (en) | 2005-03-04 | 2007-06-14 | Alsgen, Inc. | Modulation of neurodegenerative diseases |
| DE602006016928D1 (de) | 2005-03-15 | 2010-10-28 | Fujifilm Corp | Oberflächenbehandlungsverfahren unter verwendung einer scheibenartigen verbindung, (schmier)zusammensetzung zur oberflächenbehandlung und oberflächenbehandelter gegenstand |
| US20060156481A1 (en) | 2005-03-22 | 2006-07-20 | The Procter & Gamble Company | Keratin dyeing compounds, keratin dyeing compositions containing them, and use thereof |
| EP1863774A4 (en) | 2005-03-31 | 2009-07-15 | Third Order Nanotechnologies I | HETEROCYCLIC CHROMOPHORARY ARCHITECTURES WITH NEW ELECTRONIC ACCEPTOR SYSTEMS |
| US8796280B2 (en) | 2005-04-21 | 2014-08-05 | Merck Serono, S.A. | 2,3-disubstituted pyrazinesulfonamides as CRTH2 inhibitors |
| JP5033119B2 (ja) | 2005-04-25 | 2012-09-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | キナーゼ阻害剤としての新規アザ複素環化合物 |
| WO2006119800A1 (en) | 2005-05-09 | 2006-11-16 | Technische Universität Braunschweig | Light emitting compound for electroluminescent applications |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| AR056867A1 (es) | 2005-06-27 | 2007-10-31 | Bristol Myers Squibb Co | Antagonistas heterociclicos n- enlazados del receptor de p2y1 utiles en el tratamiento de condiciones tromboticas. composiciones farmaceuticas. |
| EP1899299B1 (en) | 2005-06-27 | 2010-10-20 | Bristol-Myers Squibb Company | C-linked cyclic antagonists of p2y1 receptor useful in the treatment of thrombotic conditions |
| WO2007011721A1 (en) | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
| WO2007011759A2 (en) | 2005-07-15 | 2007-01-25 | Kalypsys, Inc. | Inhibitors of mitotic kinesin |
| JP2007056213A (ja) | 2005-08-26 | 2007-03-08 | Fujifilm Corp | 焼結含油軸受油用組成物、並びにそれを用いた軸受け装置及び摺動部材 |
| PE20110285A1 (es) | 2005-10-19 | 2011-06-04 | Gruenenthal Chemie | Derivados de sulfonamidofenil propionamida como ligandos del receptor vaniloide del subtipo 1 |
| FR2892859B1 (fr) | 2005-10-27 | 2008-06-06 | Commissariat Energie Atomique | Procede de greffage de molecules d'interet sur des surfaces inorganiques, surfaces obtenues et applications |
| WO2007062222A2 (en) | 2005-11-22 | 2007-05-31 | University Of South Florida | Inhibition of cell proliferation |
| WO2007064869A2 (en) | 2005-12-01 | 2007-06-07 | Yale University | Catalysts for aryl sulfide synthesis and method of producing aryl sulfides |
| JP2008007634A (ja) | 2006-06-29 | 2008-01-17 | Fujifilm Corp | 潤滑剤組成物 |
| JP2010501570A (ja) | 2006-08-23 | 2010-01-21 | エックスティーエル バイオファーマシューティカルズ リミテッド | ４−チオ置換キノリンおよびナフチリジン化合物 |
| WO2008028553A1 (en) | 2006-09-02 | 2008-03-13 | Merck Patent Gmbh | Particle beam process for the alignment of reactive mesogens |
| WO2008118626A2 (en) | 2007-03-08 | 2008-10-02 | Burnham Institute For Medical Research | Inhibitors of jnk and methods for identifying inhibitors of jnk |
| US7956020B2 (en) | 2007-03-29 | 2011-06-07 | Fujifilm Corporation | Lubricant composition, mechanical element, and method for producing triazine derivatives |
| WO2008125811A1 (en) | 2007-04-11 | 2008-10-23 | Astrazeneca Ab | N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS |
| JP5539864B2 (ja) | 2007-06-12 | 2014-07-02 | アカオゲン，インコーポレーテッド | 抗菌剤 |
| US8063165B2 (en) | 2007-06-18 | 2011-11-22 | Bridgestone Corporation | Functional polymers prepared with sulfur-containing initiators |
| JP2009013314A (ja) | 2007-07-06 | 2009-01-22 | Toyo Ink Mfg Co Ltd | 光硬化型インキ |
| KR101558193B1 (ko) | 2007-08-21 | 2015-10-12 | 세노믹스, 인코포레이티드 | 인간 ｔ2ｒ 쓴맛 수용체 및 이의 용도 |
| US8143276B2 (en) | 2007-08-22 | 2012-03-27 | Xtl Biopharmaceuticals Ltd. | 4-thio substituted quinoline and naphthyridine compounds |
| US8907091B2 (en) | 2007-08-29 | 2014-12-09 | Methylgene Inc. | Processes and intermediates for preparing fused heterocyclic kinase inhibitors |
| WO2009030318A1 (de) | 2007-08-29 | 2009-03-12 | Merck Patent Gmbh | Flüssigkristallanzeige |
| AU2008298948B2 (en) | 2007-09-12 | 2014-09-04 | F. Hoffmann-La Roche Ag | Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use |
| US9340506B2 (en) | 2007-10-08 | 2016-05-17 | Advinus Therapeutics Limited | Acetamide derivatives as glucokinase activators, their process and medicinal applications |
| US8501955B2 (en) | 2007-10-08 | 2013-08-06 | Advinus Therapeutics Private Limited | Acetamide derivatives as glucokinase activators, their process and medicinal application |
| US8354528B2 (en) | 2007-10-25 | 2013-01-15 | Genentech, Inc. | Process for making thienopyrimidine compounds |
| BRPI0817897A2 (pt) | 2007-11-02 | 2019-09-24 | Methylgene Inc | composto, composição, e, métodos de inibição da atividade hdac, e de tratamento de uma doença responsiva a um inibidor de atividade hdac |
| US8304553B2 (en) | 2007-12-19 | 2012-11-06 | Nanyang Technological University | Method of forming oseltamivir and derivatives thereof |
| EP2098226A1 (de) | 2008-03-06 | 2009-09-09 | Forschungsverbund Berlin e.V. | AKAP-PKA-Interaktionshemmer zur Anwendung in der Behandlung von Herzkrankheiten |
| US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
| US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
| WO2010011666A2 (en) | 2008-07-21 | 2010-01-28 | University Of South Florida | Indoline scaffold shp-2 inhibitors and cancer treatment method |
| KR101612577B1 (ko) | 2008-07-28 | 2016-04-14 | 메르크 파텐트 게엠베하 | 액정 디스플레이 |
| WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
| EP2361290B1 (de) | 2008-12-22 | 2013-05-22 | Merck Patent GmbH | Flüssigkristallanzeige |
| WO2010075273A1 (en) | 2008-12-23 | 2010-07-01 | Schering Corporation | Bicyclic heterocycle derivatives and methods of use thereof |
| DE102010006691A1 (de) | 2009-02-06 | 2010-10-28 | Merck Patent Gmbh | Flüssigkristallines Medium und Flüssigkristallanzeige |
| US20120077959A1 (en) | 2009-02-16 | 2012-03-29 | Zhang X Peter | Asymmetric Cobalt-Catalyzed Cyclopropanation With Succinimidyl Diazoacetate |
| WO2010096777A1 (en) | 2009-02-23 | 2010-08-26 | Presidio Pharmaceuticals, Inc. | Inhibitors of hcv ns5a |
| JP2010217692A (ja) | 2009-03-18 | 2010-09-30 | Konica Minolta Holdings Inc | 表示素子 |
| US8815918B2 (en) | 2009-04-02 | 2014-08-26 | Centro Nacional De Investigaciones Oncologicas (Cnio) | Imidazo [2, 1-B] [1, 3, 4] thiadiazole derivatives |
| WO2010115098A2 (en) | 2009-04-03 | 2010-10-07 | The Scripps Research Institute | Palladium-catalyzed ortho-fluorination |
| DE102010012900A1 (de) | 2009-04-23 | 2010-11-25 | Merck Patent Gmbh | Flüssigkristallanzeige |
| KR101705158B1 (ko) | 2009-05-05 | 2017-02-09 | 다나-파버 캔서 인스티튜트 인크. | Ｅｇｆｒ 억제제 및 질환 치료방법 |
| WO2011005355A1 (en) | 2009-05-07 | 2011-01-13 | Achaogen, Inc. | Combinations comprising a lpxc inhibitor and an antibiotic for use in the treatment of infections caused by gram-negative bacteria |
| US20120245158A1 (en) | 2009-06-16 | 2012-09-27 | Xianhai Huang | Gamma secretase modulators |
| EP2443118A1 (en) | 2009-06-16 | 2012-04-25 | Schering Corporation | Gamma secretase modulators |
| WO2010147969A2 (en) | 2009-06-16 | 2010-12-23 | Schering Corporation | Gamma secretase modulators |
| CA2937222C (en) | 2009-06-25 | 2019-06-04 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds |
| WO2010148422A1 (en) | 2009-06-25 | 2010-12-29 | Walter And Eliza Hall Institute Of Medical Research | Compounds and methods for treating parasitic infestations |
| US20120149663A1 (en) | 2009-08-18 | 2012-06-14 | Georgetown University | Boronic acid compositions and methods related to cancer |
| CA2772790C (en) | 2009-09-04 | 2017-06-27 | Benjamin Bader | Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors |
| EP2292720A1 (en) | 2009-09-08 | 2011-03-09 | Merck Patent GmbH | Liquid-crystal display |
| US8877930B2 (en) | 2009-11-04 | 2014-11-04 | Massachusetts Institute Of Technology | Continuous flow synthesis of amino alcohols using microreactors |
| KR20110088098A (ko) | 2010-01-28 | 2011-08-03 | 다우어드밴스드디스플레이머티리얼 유한회사 | 신규한 유기 발광 화합물 및 이를 채용하고 있는 유기 전계 발광 소자 |
| PH12012501662A1 (en) | 2010-02-18 | 2012-10-22 | Centro Nac De Investigaciones Oncologicas Cnio | Triazolo [4,5 - b] pyridin derivatives |
| MX2012010115A (es) | 2010-03-01 | 2013-02-26 | Gtx Inc | Compuestos para el tratamiento de cancer. |
| KR20110101444A (ko) | 2010-03-08 | 2011-09-16 | 다우어드밴스드디스플레이머티리얼 유한회사 | 신규한 유기 발광 화합물 및 이를 포함하는 유기 발광 소자 |
| KR20110104765A (ko) | 2010-03-17 | 2011-09-23 | 다우어드밴스드디스플레이머티리얼 유한회사 | 신규한 유기 발광 화합물 및 이를 채용하고 있는 유기 전계 발광 소자 |
| WO2011133871A2 (en) | 2010-04-22 | 2011-10-27 | Alnylam Pharmaceuticals, Inc. | 5'-end derivatives |
| US8598164B2 (en) | 2010-05-06 | 2013-12-03 | Vertex Pharmaceuticals Incorporated | Heterocyclic chromene-spirocyclic piperidine amides as modulators of ion channels |
| NZ603789A (en) | 2010-05-26 | 2015-03-27 | Sunovion Pharmaceuticals Inc | Heteroaryl compounds and methods of use thereof |
| SG186085A1 (en) | 2010-06-03 | 2013-01-30 | Alnylam Pharmaceuticals Inc | Biodegradable lipids for the delivery of active agents |
| WO2012016133A2 (en) | 2010-07-29 | 2012-02-02 | President And Fellows Of Harvard College | Ros1 kinase inhibitors for the treatment of glioblastoma and other p53-deficient cancers |
| BR112013002112B1 (pt) | 2010-07-29 | 2021-04-06 | Rigel Pharmaceuticals, Inc. | Composto, composição farmacêutica, e, uso de um composto, ou de um respectivo sal farmaceuticamente aceitável, ou de uma composição |
| WO2012016188A2 (en) | 2010-07-30 | 2012-02-02 | Alnylam Pharmaceuticals, Inc. | Methods and compositions for delivery of active agents |
| WO2012020357A1 (en) | 2010-08-09 | 2012-02-16 | Advinus Therapeutics Ltd. | Acetamide compounds, their process and pharmaceutical application |
| WO2012020215A1 (en) | 2010-08-09 | 2012-02-16 | Centro Nacional De Investigaciones Oncológicas (Cnio) | Amino- imidazolothiadiazoles for use as protein or lipid kinase inhibitors |
| AR082498A1 (es) | 2010-08-20 | 2012-12-12 | Gruenenthal Gmbh | Derivados ciclicos de carboxamida y urea sustituidos como ligandos del receptor de vainiloide |
| RU2013121799A (ru) | 2010-10-14 | 2014-11-20 | Конинклейке Филипс Электроникс Н.В. | Набор для претаргетинга, способ и агенты, применяемые в нем |
| US9394290B2 (en) | 2010-10-21 | 2016-07-19 | Universitaet Des Saarlandes Campus Saarbruecken | Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases |
| WO2012056419A1 (en) | 2010-10-28 | 2012-05-03 | Basf Se | N-heterocyclic carbene complexes, their preparation and use |
| US20120108819A1 (en) | 2010-10-28 | 2012-05-03 | Basf Se | N-Heterocyclic Carbene Complexes, Their Preparation And Use |
| KR20120045905A (ko) | 2010-11-01 | 2012-05-09 | 한국화학연구원 | 헤테로고리 축합된 피리도 화합물 및 이의 제조방법 |
| US9090633B2 (en) | 2010-11-18 | 2015-07-28 | Kasina Laila Innova Pharmaceuticals Private Limited | Substituted 4-(arylamino) selenophenopyrimidine compounds and methods of use thereof |
| EP2651405A2 (en) | 2010-12-14 | 2013-10-23 | Electrophoretics Limited | Casein kinase 1 (ck1 ) inhibitors |
| RU2013133813A (ru) | 2010-12-21 | 2015-01-27 | Конинклейке Филипс Электроникс Н.В. | Средства для выведения биомолекул из кровотока |
| WO2012088438A1 (en) | 2010-12-22 | 2012-06-28 | Eutropics Pharmaceuticals, Inc. | Compositions and methods useful for treating diseases |
| JP5618815B2 (ja) | 2010-12-24 | 2014-11-05 | 富士フイルム株式会社 | 感活性光線性又は感放射線性樹脂組成物、並びに、この組成物を用いた感活性光線性又は感放射線性膜及びパターン形成方法 |
| US8883793B2 (en) | 2010-12-29 | 2014-11-11 | Development Center For Biotechnology | Tubulin inhibitors and methods of using the same |
| EP2678050B1 (en) | 2011-02-24 | 2020-10-14 | Emory University | Noggin blocking compositions for ossification and methods related thereto |
| CN103502218B (zh) | 2011-03-04 | 2016-08-17 | 生命科技公司 | 用于缀合生物分子的化合物和方法 |
| DE102012003796A1 (de) | 2011-03-18 | 2012-09-20 | Merck Patent Gmbh | Flüssigkristallines Medium |
| WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| GB2503629B (en) | 2011-03-29 | 2019-04-17 | Merck Patent Gmbh | Liquid-crystalline medium |
| US20140163229A1 (en) | 2011-04-07 | 2014-06-12 | Cornell University | Silyl monomers capable of multimerizing in an aqueous solution, and methods of using same |
| EP2522369A1 (en) | 2011-05-09 | 2012-11-14 | Koninklijke Philips Electronics N.V. | Pretargeting kit, method and agents used therein |
| DK2707101T3 (da) | 2011-05-12 | 2019-05-13 | Proteostasis Therapeutics Inc | Proteostaseregulatorer |
| JP6215194B2 (ja) | 2011-05-16 | 2017-10-18 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | 生体直交型薬物活性化 |
| EP2524918A1 (en) | 2011-05-19 | 2012-11-21 | Centro Nacional de Investigaciones Oncológicas (CNIO) | Imidazopyrazines derivates as kinase inhibitors |
| JP5782836B2 (ja) | 2011-05-27 | 2015-09-24 | コニカミノルタ株式会社 | 有機エレクトロルミネッセンス素子材料、有機エレクトロルミネッセンス素子、表示装置、照明装置、並びに化合物 |
| CN103797009B (zh) | 2011-06-03 | 2017-04-26 | 麻省理工学院 | Z‑选择性闭环复分解反应 |
| EP2726532B1 (en) | 2011-06-28 | 2016-05-18 | Merck Patent GmbH | Indaceno derivatives as organic semiconductors |
| KR102082361B1 (ko) | 2011-07-07 | 2020-04-14 | 메르크 파텐트 게엠베하 | 액정 매질 |
| JP2014532084A (ja) | 2011-07-08 | 2014-12-04 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ | 共役ポリマー |
| EP2753605B1 (en) | 2011-09-09 | 2019-03-27 | Lantheus Medical Imaging, Inc. | Compositions, methods, and systems for the synthesis and use of imaging agents |
| MX352672B (es) | 2011-09-27 | 2017-12-04 | Amgen Inc | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. |
| EP2615083A1 (en) | 2012-01-10 | 2013-07-17 | Studiengesellschaft Kohle mbH | Process for the asymmetric oxidation of organic compounds with peroxides in the presence of a chiral acid catalyst |
| JP5814141B2 (ja) | 2012-01-23 | 2015-11-17 | ユー・ディー・シー アイルランド リミテッド | 合成法、その合成法を用いて合成された化合物および有機電界発光素子 |
| KR102251706B1 (ko) | 2012-02-22 | 2021-05-14 | 메르크 파텐트 게엠베하 | 액정 매질 |
| EP2834313A1 (en) | 2012-04-03 | 2015-02-11 | 3M Innovative Properties Company | Crosslinkable composition comprising photobase generators |
| UA115663C2 (uk) | 2012-04-20 | 2017-12-11 | Байєр Кропсайнс Аг | (тіо)карбоксамідні похідні n-циклоалкіл-n-[(гетероциклілфеніл)метилену] |
| FR2992317B1 (fr) | 2012-06-22 | 2016-05-13 | Diverchim | Procede de preparation de peptides chiraux |
| US8575283B1 (en) | 2012-06-28 | 2013-11-05 | Formosa Plastics Corporation, U.S.A. | Heterocyclic organic compounds as electron donors for polyolefin catalysts |
| WO2014031872A2 (en) | 2012-08-23 | 2014-02-27 | The Broad Institute, Inc. | Small molecule inhibitors for treating parasitic infections |
| RS61242B1 (sr) | 2012-09-04 | 2021-01-29 | Shanghai hengrui pharmaceutical co ltd | Derivati imidazolina, postupci njihove pripreme i njihove primene u medicini |
| IN2015DN02008A (https=) | 2012-09-21 | 2015-08-14 | Advinus Therapeutics Ltd | |
| CN104769465A (zh) | 2012-10-29 | 2015-07-08 | 柯尼卡美能达株式会社 | 相位差膜、圆偏振片和图像显示装置 |
| JP2016501284A (ja) | 2012-11-16 | 2016-01-18 | ビーエーエスエフ ソシエタス・ヨーロピアＢａｓｆ Ｓｅ | フルオロポリマーシール適合性向上のためのエポキシ化合物含有潤滑油組成物 |
| AU2013348116A1 (en) * | 2012-11-20 | 2015-06-11 | Principia Biopharma Inc. | Azaindole derivatives as JAK3 inhibitors |
| WO2014081300A1 (en) | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Channel protein activatable liposomes |
| US20150297741A1 (en) | 2012-11-22 | 2015-10-22 | Tagworks Pharmaceuticals B.V. | Bio-orthogonal drug activation |
| WO2014081299A1 (en) | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Activatable liposomes |
| WO2014081303A1 (en) | 2012-11-22 | 2014-05-30 | Tagworks Pharmaceuticals B.V. | Chemically cleavable group |
| US9580653B2 (en) | 2012-12-12 | 2017-02-28 | Merck Patent Gmbh | Liquid-crystalline medium |
| JP6335428B2 (ja) | 2012-12-21 | 2018-05-30 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子および電子機器 |
| EP2941469A2 (de) | 2013-01-03 | 2015-11-11 | Merck Patent GmbH | Materialien für elektronische vorrichtungen |
| JP6322587B2 (ja) | 2013-02-08 | 2018-05-09 | 株式会社Ｊｏｌｅｄ | 有機エレクトロルミネッセンス素子 |
| WO2014127350A1 (en) | 2013-02-18 | 2014-08-21 | The Scripps Research Institute | Modulators of vasopressin receptors with therapeutic potential |
| WO2014134127A1 (en) | 2013-02-26 | 2014-09-04 | Northeastern University | Cannabinergic nitrate esters and related analogs |
| US9487472B2 (en) | 2013-02-26 | 2016-11-08 | President And Fellows Of Harvard College | Synthesis of acyclic and cyclic amines using iron-catalyzed nitrene group transfer |
| US9963452B2 (en) | 2013-03-14 | 2018-05-08 | Augusta Pharmaceuticals Inc. | Methods, compounds, and compositions for inhibition of ROS |
| US9290528B1 (en) | 2013-03-15 | 2016-03-22 | University Of Kentucky Research Foundation | Light-activated compounds |
| JP5902641B2 (ja) | 2013-03-27 | 2016-04-13 | 富士フイルム株式会社 | 光干渉顔料およびその製造方法 |
| AU2014247953A1 (en) | 2013-04-05 | 2015-11-12 | Mitobridge, Inc. | PPAR agonists |
| JP6553022B2 (ja) | 2013-04-08 | 2019-07-31 | メルク パテント ゲーエムベーハー | 有機エレクトロルミネッセント素子 |
| EP2984692B1 (de) | 2013-04-08 | 2018-01-31 | Merck Patent GmbH | Organische elektrolumineszenzvorrichtung mit thermisch aktiviertem verzögertem fluoreszenzmaterial |
| AU2014256984B2 (en) | 2013-04-26 | 2019-02-14 | Indiana University Research & Technology Corporation | Hydroxyindole carboxylic acid based inhibitors for oncogenic Src homology-2 domain containing protein tyrosine phosphatase-2 (SHP2) |
| JP2014232188A (ja) | 2013-05-29 | 2014-12-11 | コニカミノルタ株式会社 | セルロースアシレートフィルム、円偏光板及び画像表示装置 |
| WO2015003146A1 (en) | 2013-07-03 | 2015-01-08 | Georgetown University | Boronic acid derivatives of resveratrol for activating deacetylase enzymes |
| EP3016652A4 (en) | 2013-07-03 | 2017-03-08 | Indiana University Research and Technology Corporation | Shp2 inhibitors and methods of treating autoimmune and/or glomerulonephritis-associated diseases using shp2 inhibitors |
| WO2015003137A1 (en) | 2013-07-03 | 2015-01-08 | University Of Connecticut | Polymerization of diene monomers |
| GB201312991D0 (en) | 2013-07-19 | 2013-09-04 | Isis Innovation | Process |
| TWI648383B (zh) | 2013-08-02 | 2019-01-21 | 德商馬克專利公司 | 液晶介質 |
| EP3046924A1 (en) | 2013-09-20 | 2016-07-27 | IDENIX Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| US20160257657A1 (en) | 2013-09-20 | 2016-09-08 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Small molecule inhibitors of the nuclear translocation of androgen receptor for the treatment of castration-resistant prostate cancer |
| WO2015048547A2 (en) | 2013-09-26 | 2015-04-02 | Rigel Pharmaceuticals, Inc. | Methods for using and biomarkers for ampk-activating compounds |
| KR101628288B1 (ko) | 2013-09-30 | 2016-06-08 | 주식회사 엘지화학 | 음성 광학 분산도를 갖는 광학 소자 제조용 조성물 및 이로부터 제조된 광학 이방체 |
| EP2857405A1 (en) | 2013-10-01 | 2015-04-08 | Studiengesellschaft Kohle mbH | Process for the trans-selective hydroboration of internal alkynes |
| BR112016008632A8 (pt) | 2013-10-21 | 2020-03-17 | Merck Patent Gmbh | compostos de heteroarila como inibidores de btk, seus usos, e composição farmacêutica |
| JP6088995B2 (ja) | 2013-10-24 | 2017-03-01 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子および電子機器 |
| JP6522313B2 (ja) | 2013-10-24 | 2019-05-29 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子および電子機器 |
| KR101537860B1 (ko) | 2013-11-22 | 2015-07-20 | 롯데케미칼 주식회사 | 내감마선 성능이 향상된 폴리카보네이트 수지 조성물 및 이를 이용한 성형품 |
| JP6215674B2 (ja) | 2013-11-29 | 2017-10-18 | 出光興産株式会社 | 有機エレクトロルミネッセンス素子および電子機器 |
| JP6309834B2 (ja) | 2013-12-11 | 2018-04-11 | 株式会社Adeka | 着色性組成物 |
| JP2015163671A (ja) | 2013-12-13 | 2015-09-10 | 株式会社Adeka | ラジカル重合性組成物 |
| US10131841B2 (en) | 2013-12-16 | 2018-11-20 | Merck Patent Gmbh | Liquid-crystalline medium |
| US10020455B2 (en) | 2014-01-07 | 2018-07-10 | Arizona Board Of Regents On Behalf Of Arizona State University | Tetradentate platinum and palladium complex emitters containing phenyl-pyrazole and its analogues |
| US10087151B2 (en) | 2014-01-09 | 2018-10-02 | The J. David Gladstone Institutes, A Testimentary Trust Established Under The Will Of J. David Gladstone | Substituted benzoxazine and related compounds |
| CN105899493B (zh) | 2014-01-17 | 2019-03-29 | 诺华股份有限公司 | 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物 |
| JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
| JP6523303B2 (ja) | 2014-01-17 | 2019-05-29 | ノバルティス アーゲー | Ｓｈｐ２の活性を阻害するための１−ピリダジン／トリアジン−３−イル−ピペラジン／ピペリジン／ピロリジン誘導体およびその組成物 |
| KR20150091942A (ko) | 2014-02-04 | 2015-08-12 | 삼성전자주식회사 | 유기금속 화합물 및 이를 포함한 유기 발광 소자 |
| JP6313604B2 (ja) | 2014-02-05 | 2018-04-18 | 富士フイルム株式会社 | 感活性光線性又は感放射線性樹脂組成物、感活性光線性又は感放射線性膜、感活性光線性又は感放射線性膜を備えたマスクブランクス、パターン形成方法、及び電子デバイスの製造方法 |
| EP3110794A1 (en) | 2014-02-27 | 2017-01-04 | Merck Patent GmbH | Heterocyclic compounds as nav channel inhibitors and uses thereof |
| JP2017508798A (ja) | 2014-03-07 | 2017-03-30 | ザ ジョンズ ホプキンス ユニバーシティ | ヒストンリジン特異的デメチラーゼ（ｌｓｄ１）およびヒストンデアセチラーゼ（ｈｄａｃ）の阻害剤 |
| RS61810B1 (sr) | 2014-05-13 | 2021-06-30 | Hoffmann La Roche | Deuterisana heterociklična jedinjenja i njihova upotreba kao sredstva za snimanje |
| EP3142637B1 (en) | 2014-05-16 | 2020-07-29 | Olaplex, Inc. | Keratin treatment formulations and methods |
| ES2842592T3 (es) | 2014-05-19 | 2021-07-14 | Boehringer Ingelheim Animal Health Usa Inc | Compuestos antihelmínticos |
| WO2015187905A1 (en) | 2014-06-05 | 2015-12-10 | Merck Patent Gmbh | Novel quinoline derivatives and their use in neurodegenerative diseases |
| US20170174826A1 (en) | 2014-07-16 | 2017-06-22 | Agency For Science, Technology And Research | Donor-acceptor polymers |
| US9818959B2 (en) | 2014-07-29 | 2017-11-14 | Arizona Board of Regents on behlaf of Arizona State University | Metal-assisted delayed fluorescent emitters containing tridentate ligands |
| WO2016022645A1 (en) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| EP2985334B1 (en) | 2014-08-15 | 2018-06-20 | Merck Patent GmbH | Liquid-crystalline medium |
| EP3188271B1 (en) | 2014-08-26 | 2022-05-04 | Idemitsu Kosan Co., Ltd | Organic electroluminescent element and electronic device |
| EP2991153B1 (en) | 2014-08-28 | 2023-08-23 | Samsung Electronics Co., Ltd. | Composite electrolyte and lithium battery including the same |
| WO2016049565A1 (en) | 2014-09-25 | 2016-03-31 | Araxes Pharma Llc | Compositions and methods for inhibition of ras |
| JP2017537940A (ja) | 2014-12-10 | 2017-12-21 | マサチューセッツ インスティテュート オブ テクノロジー | 増殖性疾患の処置に有用な融合１，３−アゾール誘導体 |
| KR102384224B1 (ko) | 2014-12-30 | 2022-04-08 | 삼성전자주식회사 | 축합환 화합물 및 이를 포함한 유기 발광 소자 |
| WO2016145383A1 (en) | 2015-03-11 | 2016-09-15 | Board Of Regents, University Of Texas System | Mth1 inhibitors for treating disease |
| KR102434696B1 (ko) | 2015-03-13 | 2022-08-22 | 삼성전자주식회사 | 유기금속 화합물 및 이를 포함한 유기 발광 소자 |
| JP2018513853A (ja) | 2015-04-10 | 2018-05-31 | アラクセス ファーマ エルエルシー | 置換キナゾリン化合物およびその使用方法 |
| JP6789239B2 (ja) | 2015-04-15 | 2020-11-25 | アラクセス ファーマ エルエルシー | Ｋｒａｓの縮合三環系インヒビターおよびその使用の方法 |
| KR102114536B1 (ko) | 2015-05-07 | 2020-05-22 | 브리스톨-마이어스 스큅 컴퍼니 | RORγ 조정제로서의 트리시클릭 술폰 |
| US9458308B1 (en) | 2015-05-12 | 2016-10-04 | Lotte Chemical Corporation | Polycarbonate resin composition with increased gamma-radiation resistant property and molded article using the same |
| US9879039B2 (en) | 2015-06-03 | 2018-01-30 | Arizona Board Of Regents On Behalf Of Arizona State University | Tetradentate and octahedral metal complexes containing naphthyridinocarbazole and its analogues |
| ES2741746T3 (es) | 2015-06-19 | 2020-02-12 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
| CN112625028B (zh) | 2015-06-19 | 2024-10-29 | 诺华股份有限公司 | 用于抑制shp2活性的化合物和组合物 |
| FR3037952B1 (fr) | 2015-06-24 | 2019-01-25 | Compagnie Generale Des Etablissements Michelin | Procede de synthese d'oximes aromatiques |
| EP3112440B1 (en) | 2015-07-02 | 2019-07-24 | Merck Patent GmbH | Liquid-crystal medium |
| MX388781B (es) | 2015-07-22 | 2025-03-20 | Araxes Pharma Llc | Compuestos de quinazolina sustituido y su uso como inhibidores de proteínas kras, hras y/o nras mutantes g12c. |
| GB201514015D0 (en) | 2015-08-07 | 2015-09-23 | Arnér Elias S J And Dept Of Health And Human Services | Novel pyridazinones and their use in the treatment of cancer |
| GB201514018D0 (en) | 2015-08-07 | 2015-09-23 | Arnér Elias S J And United States Of America Asrepresented By The Sec Dep Of Health And Human Servic | Novel tricyclic compounds and their use in the treatment of cancer |
| US10201531B2 (en) | 2015-08-12 | 2019-02-12 | Mochida Pharmaceutical Co., Ltd. | Indazolyl-oxo-isothiazole compounds |
| EP3133078B1 (en) | 2015-08-18 | 2019-01-30 | Samsung Electronics Co., Ltd. | Organometallic compound and organic light-emitting device including the same |
| KR101796227B1 (ko) | 2015-08-21 | 2017-11-10 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| US10240085B2 (en) | 2015-08-27 | 2019-03-26 | Samsung Electronics Co., Ltd. | Thin film and organic light-emitting device including the same |
| KR102542465B1 (ko) | 2015-09-22 | 2023-06-12 | 삼성전자주식회사 | 유기금속 화합물 및 이를 포함한 유기 발광 소자 |
| US10882847B2 (en) | 2015-09-28 | 2021-01-05 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058902A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| EP3356354A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| EP3356353A1 (en) | 2015-09-28 | 2018-08-08 | Araxes Pharma LLC | Inhibitors of kras g12c mutant proteins |
| WO2017058807A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| US10647703B2 (en) | 2015-09-28 | 2020-05-12 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| WO2017058915A1 (en) | 2015-09-28 | 2017-04-06 | Araxes Pharma Llc | Inhibitors of kras g12c mutant proteins |
| SE541053C2 (sv) | 2015-09-30 | 2019-03-19 | Epiroc Rock Drills Ab | System och förfarande för borrplansgenerering, borrigg, datorprogram samt datorprogramprodukt |
| WO2017066705A1 (en) | 2015-10-14 | 2017-04-20 | Aquinnah Pharmaceuticals, Inc. | Compounds, compositions and methods of use against stress granules |
| JP2018533939A (ja) | 2015-10-19 | 2018-11-22 | アラクセス ファーマ エルエルシー | Ｒａｓの阻害剤をスクリーニングするための方法 |
| EP3162875B1 (en) | 2015-10-30 | 2018-05-23 | Merck Patent GmbH | Polymerisable compounds and the use thereof in liquid-crystal displays |
| ES2895904T3 (es) | 2015-11-02 | 2022-02-23 | Genase Therapeutics B V | Tetrahidroindazoles y usos médicos de los mismos |
| KR20180081596A (ko) * | 2015-11-16 | 2018-07-16 | 아락세스 파마 엘엘씨 | 치환된 헤테로사이클릭 그룹을 포함하는 2-치환된 퀴나졸린 화합물 및 이의 사용 방법 |
| WO2017100546A1 (en) | 2015-12-09 | 2017-06-15 | Araxes Pharma Llc | Methods for preparation of quinazoline derivatives |
| KR20170069342A (ko) | 2015-12-10 | 2017-06-21 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| CN106892924B (zh) | 2015-12-17 | 2021-01-08 | 四川科伦博泰生物医药股份有限公司 | 短效苯并二氮*衍生物、其制备方法及其用途 |
| KR20170075118A (ko) | 2015-12-22 | 2017-07-03 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| KR102579752B1 (ko) | 2015-12-22 | 2023-09-19 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| US10336772B2 (en) | 2015-12-28 | 2019-07-02 | Samsung Electronics Co., Ltd. | Bicarbazole compound, material for organic light-emitting device including bicarbazole compound, and organic light-emitting device including bicarbazole compound |
| KR102419178B1 (ko) | 2015-12-29 | 2022-07-11 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| KR102396293B1 (ko) | 2015-12-29 | 2022-05-11 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| WO2017117239A1 (en) | 2015-12-30 | 2017-07-06 | Flatley Discovery Lab, Llc | Compounds and methods for the treatment of cystic fibrosis |
| EP3190164B1 (en) | 2016-01-05 | 2019-07-24 | Samsung Electronics Co., Ltd | Composition, thin film including the composition, and organic light-emitting device including the composition or the thin film |
| KR102633852B1 (ko) | 2016-01-25 | 2024-02-07 | 삼성디스플레이 주식회사 | 카바졸계 화합물 및 이를 포함한 유기 발광 소자 |
| EP3414216B1 (en) | 2016-02-08 | 2020-10-21 | AAA Chemistry ApS | Arylation of aliphatic amines |
| KR102628850B1 (ko) | 2016-03-07 | 2024-01-25 | 삼성디스플레이 주식회사 | 축합환 화합물 및 이를 포함한 유기 발광 소자 |
| US11179710B2 (en) | 2016-03-09 | 2021-11-23 | President And Fellows Of Harvard College | Direct palladium-catalyzed aromatic fluorination |
| CN109152784B (zh) | 2016-03-16 | 2021-12-28 | 库拉肿瘤学公司 | 经取代的menin-mll抑制剂及使用方法 |
| WO2017172979A1 (en) | 2016-03-30 | 2017-10-05 | Araxes Pharma Llc | Substituted quinazoline compounds and methods of use |
| WO2017170263A1 (ja) | 2016-03-31 | 2017-10-05 | 株式会社Ｄｎｐファインケミカル | 感光性着色樹脂組成物、カラーフィルタ及びその製造方法、並びに表示装置 |
| KR102606277B1 (ko) | 2016-04-06 | 2023-11-27 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| KR102642199B1 (ko) | 2016-04-07 | 2024-03-05 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| JP7039489B2 (ja) | 2016-05-18 | 2022-03-22 | ミラティ セラピューティクス， インコーポレイテッド | Ｋｒａｓ ｇ１２ｃ阻害剤 |
| AU2017274199B2 (en) | 2016-05-31 | 2021-09-23 | Board Of Regents, The University Of Texas System | Heterocyclic inhibitors of PTPN11 |
| EA202092441A1 (ru) * | 2016-06-07 | 2021-05-21 | Джакобио Фармасьютикалс Ко., Лтд. | Новые гетероциклические производные, применимые в качестве ингибиторов shp2 |
| KR102666178B1 (ko) | 2016-06-07 | 2024-05-14 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| MX383856B (es) | 2016-06-14 | 2025-03-14 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de shp2. |
| TW201805000A (zh) | 2016-06-20 | 2018-02-16 | 庫拉腫瘤技術股份有限公司 | 利用erk抑制劑之鱗狀細胞癌之治療 |
| US20180002604A1 (en) | 2016-06-30 | 2018-01-04 | Merck Patent Gmbh | Liquid-crystalline medium |
| WO2018027892A1 (en) | 2016-08-12 | 2018-02-15 | Eli Lilly And Company | Amino pyrimidine ssao inhibitors |
| US11299673B2 (en) | 2016-08-12 | 2022-04-12 | Merck Patent Gmbh | Liquid-crystal medium |
| KR102721990B1 (ko) | 2016-08-16 | 2024-10-29 | 삼성디스플레이 주식회사 | 유기 발광 소자 |
| WO2018035477A1 (en) | 2016-08-19 | 2018-02-22 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| US11529347B2 (en) | 2016-09-22 | 2022-12-20 | Relay Therapeutics, Inc. | SHP2 phosphatase inhibitors and methods of use thereof |
| JP6589795B2 (ja) | 2016-09-27 | 2019-10-16 | 信越化学工業株式会社 | スルホニウム塩、レジスト組成物及びパターン形成方法 |
| WO2018060110A1 (en) | 2016-09-28 | 2018-04-05 | Merck Patent Gmbh | Polymerisable liquid crystal material and polymerised liquid crystal film |
| US10280172B2 (en) | 2016-09-29 | 2019-05-07 | Araxes Pharma Llc | Inhibitors of KRAS G12C mutant proteins |
| US11424410B2 (en) | 2016-09-29 | 2022-08-23 | Sumitomo Chemical Company, Limited | Light emitting device |
| EP3523289A1 (en) | 2016-10-07 | 2019-08-14 | Araxes Pharma LLC | Heterocyclic compounds as inhibitors of ras and methods of use thereof |
| ES2872005T3 (es) | 2016-10-13 | 2021-11-02 | Bristol Myers Squibb Co | Sulfonas heterocíclicas como moduladores de ROR gamma |
| TW202500565A (zh) | 2016-10-24 | 2025-01-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
| US10435369B2 (en) | 2016-11-09 | 2019-10-08 | Bristol-Myers Squibb Company | Tricyclic sulfones as ROR gamma modulators |
| WO2018119263A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds derivatives as pd-l1 internalization inducers |
| WO2018119183A2 (en) | 2016-12-22 | 2018-06-28 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| US20190343836A1 (en) | 2017-01-10 | 2019-11-14 | Novartis Ag | Pharmaceutical combination comprising an alk inhibitor and a shp2 inhibitor |
| MX2019008696A (es) | 2017-01-23 | 2019-09-13 | Revolution Medicines Inc | Compuestos de piridina como inhibidores de shp2 alostericos. |
| MX2019008695A (es) | 2017-01-23 | 2019-09-11 | Revolution Medicines Inc | Compuestos biciclicos como inhibidores alostericos de shp2. |
| AU2018218519B2 (en) | 2017-02-07 | 2021-08-05 | Oblique Therapeutics Ab | Heteroarylsulfonyl-substituted pyridines and their use in the treatment of cancer |
| US11168069B2 (en) | 2017-02-07 | 2021-11-09 | Oblique Therapeutics Ab | Heterocyclylsulfonyl-substituted pyridines and their use in the treatment of cancer |
| WO2018161033A1 (en) | 2017-03-02 | 2018-09-07 | Wright, Adrian | Small molecule ire1-alpha inhibitors |
| KR20240026521A (ko) | 2017-03-23 | 2024-02-28 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
| KR102395784B1 (ko) | 2017-03-27 | 2022-05-10 | 삼성전자주식회사 | 유기금속 화합물 및 이를 포함한 유기 발광 소자 |
| KR102461719B1 (ko) | 2017-05-23 | 2022-11-01 | 삼성전자주식회사 | 유기금속 화합물, 이를 포함한 유기 발광 소자 및 이를 포함한 진단용 조성물 |
| WO2018218133A1 (en) | 2017-05-26 | 2018-11-29 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| WO2018230595A1 (ja) | 2017-06-14 | 2018-12-20 | 富士フイルム株式会社 | 組成物、膜、レンズ、固体撮像素子、化合物 |
| KR20180137311A (ko) | 2017-06-16 | 2018-12-27 | 삼성전자주식회사 | 유기금속 화합물, 이를 포함한 유기 발광 소자 및 이를 포함한 진단용 조성물 |
| US20200123115A1 (en) | 2017-06-26 | 2020-04-23 | Esteve Pharmaceuticals, S.A. | Compounds having multimodal activity against pain |
| WO2019018119A1 (en) | 2017-07-18 | 2019-01-24 | Pairnomix, Llc | METHODS FOR TREATING EPILEPSY AND DISORDERS ASSOCIATED WITH KCNTI |
| KR20190014187A (ko) | 2017-07-27 | 2019-02-12 | 삼성디스플레이 주식회사 | 유기금속 화합물 및 이를 포함하는 유기 발광 소자 |
| GB201712110D0 (en) | 2017-07-27 | 2017-09-13 | Thomas Helledays Stiftelse För Medicinsk Forskning | New compounds and uses |
| JP7346015B2 (ja) | 2017-09-06 | 2023-09-19 | 住友化学株式会社 | 発光素子 |
| CA3074690A1 (en) | 2017-09-07 | 2019-03-14 | Revolution Medicines, Inc. | Shp2 inhibitor compositions and methods for treating cancer |
| WO2019051469A1 (en) | 2017-09-11 | 2019-03-14 | Krouzon Pharmaceuticals, Inc. | Octahydrocyclopenta[c]pyrrole allosteric inhibitors of shp2 |
| KR102526756B1 (ko) | 2017-09-29 | 2023-04-27 | 삼성전자주식회사 | 유기금속 화합물, 이를 포함한 유기 발광 소자 및 이를 포함한 진단용 조성물 |
| EP3687997A1 (en) | 2017-09-29 | 2020-08-05 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
| CN111148819B (zh) | 2017-09-29 | 2023-06-16 | 默克专利股份有限公司 | 可聚合化合物及其在液晶显示器中的用途 |
| MX2020003579A (es) | 2017-10-12 | 2020-07-22 | Revolution Medicines Inc | Compuestos de piridina, pirazina, y triazina como inhibidores de shp2 alostericos. |
| KR102518722B1 (ko) | 2017-11-21 | 2023-04-07 | 삼성디스플레이 주식회사 | 유기금속 화합물 및 이를 포함한 유기 발광 소자 |
| BR112020009757A2 (pt) | 2017-12-15 | 2020-11-03 | Revolution Medicines, Inc. | compostos policíclicos como inibidores alostéricos de shp2 |
| ES2971712T3 (es) | 2017-12-22 | 2024-06-06 | Hibercell Inc | Derivados de cromenopiridina como inhibidores de la fosfatidilinositol fosfato cinasa |
| US11572370B2 (en) | 2018-01-08 | 2023-02-07 | Biohaven Therapeutics Ltd. | CD16A binding agents and uses thereof |
| KR102595918B1 (ko) | 2018-01-18 | 2023-11-14 | 삼성디스플레이 주식회사 | 유기금속 화합물, 이를 포함한 유기 발광 소자 및 상기 유기 발광 소자를 포함한 유기 발광 장치 |
| CN110066277B (zh) | 2018-01-24 | 2021-07-23 | 上海璎黎药业有限公司 | 芳香杂环取代烯烃化合物、其制备方法、药物组合物和应用 |
| CN110066276B (zh) | 2018-01-24 | 2020-09-18 | 上海璎黎药业有限公司 | 芳香杂环化合物、其中间体、制备方法、药物组合物和应用 |
| KR102824606B1 (ko) | 2018-02-13 | 2025-06-25 | 삼성디스플레이 주식회사 | 유기 발광 소자 및 이를 포함한 표시 장치 |
| KR102614939B1 (ko) | 2018-02-13 | 2023-12-19 | 블루레이 테라퓨틱스 (상하이) 컴퍼니 리미티드 | 피리미딘-융합고리 화합물 및 그의 제조방법과 용도 |
| WO2019165073A1 (en) | 2018-02-21 | 2019-08-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
| NZ766835A (en) | 2018-03-02 | 2023-09-29 | Otsuka Pharma Co Ltd | Pharmaceutical compounds |
| US12520712B2 (en) | 2018-03-08 | 2026-01-06 | Samsung Display Co., Ltd. | Organic light-emitting device |
| EP3537493B1 (en) | 2018-03-09 | 2024-07-31 | Samsung Display Co., Ltd | Electronic apparatus |
| WO2019183364A1 (en) | 2018-03-21 | 2019-09-26 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof |
| RU2020133727A (ru) | 2018-03-21 | 2022-04-21 | Сучжоу Пухе Биофарма Ко., Лтд. | Ингибиторы shp2 и их применение |
| SG11202009245TA (en) | 2018-03-21 | 2020-10-29 | Relay Therapeutics Inc | Shp2 phosphatase inhibitors and methods of use thereof |
| CN108794485B (zh) | 2018-04-28 | 2020-04-24 | 北京施安泰医药技术开发有限公司 | 一类toll样受体调节剂、其药物组合物、制备方法与用途 |
| KR102611661B1 (ko) | 2018-05-02 | 2023-12-08 | 나비레 파르마, 인코퍼레이티드 | Ptpn11의 치환된 헤테로사이클릭 억제제 |
| CN110492006B (zh) | 2018-05-14 | 2020-06-12 | 江苏三月光电科技有限公司 | 一种基于含硼有机化合物的电致发光器件 |
| CN108840886A (zh) | 2018-06-22 | 2018-11-20 | 南京工业大学 | 一种铂配合物蓝光材料以及有机发光器件 |
| JP7174143B2 (ja) | 2018-07-24 | 2022-11-17 | 大鵬薬品工業株式会社 | Ｓｈｐ２活性を阻害するヘテロ二環性化合物 |
| CN108863982B (zh) | 2018-08-04 | 2022-02-01 | 南昌航空大学 | 一种吩噻嗪/吩恶嗪类化合物的有机电合成方法 |
| US11518770B2 (en) | 2018-08-06 | 2022-12-06 | Purdue Research Foundation | Sesquiterpenoid analogs |
| LT3833670T (lt) | 2018-08-10 | 2024-06-25 | Navire Pharma, Inc. | 6-(4-amino-3-metil-2-oksa-8-azaspiro[4.5]dekan-8-il)-3-(2,3-dichlorfenil)-2-metilpirimidin-4(3h)-ono dariniai ir susiję junginiai kaip ptpn11 (shp2) inhibitoriai, skirti vėžiui gydyti |
| JP7542538B2 (ja) | 2018-09-18 | 2024-08-30 | ニカング セラピューティクス， インコーポレイテッド | Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての縮合三環式環誘導体 |
| JP2022502385A (ja) | 2018-09-29 | 2022-01-11 | ノバルティス アーゲー | Ｓｈｐ２の活性を阻害するための化合物の製造方法 |
| CA3112322A1 (en) | 2018-09-29 | 2020-04-02 | Novartis Ag | Manufacture of compounds and compositions for inhibiting the activity of shp2 |
| CN113473990A (zh) | 2018-10-08 | 2021-10-01 | 锐新医药公司 | 用于治疗癌症的shp2抑制剂组合物 |
-
2019
- 2019-09-17 JP JP2021539488A patent/JP7542538B2/ja active Active
- 2019-09-17 PL PL19779687.3T patent/PL3853234T3/pl unknown
- 2019-09-17 US US17/277,293 patent/US11459340B2/en active Active
- 2019-09-17 KR KR1020217011213A patent/KR102834408B1/ko active Active
- 2019-09-17 AU AU2019344899A patent/AU2019344899B2/en active Active
- 2019-09-17 BR BR112021005082-5A patent/BR112021005082A2/pt unknown
- 2019-09-17 EP EP19779686.5A patent/EP3853233A1/en not_active Withdrawn
- 2019-09-17 US US16/573,900 patent/US20200115389A1/en not_active Abandoned
- 2019-09-17 DK DK19779687.3T patent/DK3853234T3/da active
- 2019-09-17 FI FIEP19779687.3T patent/FI3853234T3/fi active
- 2019-09-17 KR KR1020217011212A patent/KR20210060555A/ko active Pending
- 2019-09-17 PT PT197796873T patent/PT3853234T/pt unknown
- 2019-09-17 MX MX2021003158A patent/MX2021003158A/es unknown
- 2019-09-17 WO PCT/US2019/051592 patent/WO2020061103A1/en not_active Ceased
- 2019-09-17 AU AU2019344897A patent/AU2019344897B2/en active Active
- 2019-09-17 ES ES19779687T patent/ES3036496T3/es active Active
- 2019-09-17 TW TW108133442A patent/TWI827677B/zh active
- 2019-09-17 EP EP19779687.3A patent/EP3853234B1/en active Active
- 2019-09-17 SG SG11202102679QA patent/SG11202102679QA/en unknown
- 2019-09-17 CN CN201980074211.0A patent/CN112996795B/zh active Active
- 2019-09-17 JP JP2021539487A patent/JP7337174B2/ja active Active
- 2019-09-17 CA CA3113233A patent/CA3113233A1/en active Pending
- 2019-09-17 CA CA3113234A patent/CA3113234A1/en active Pending
- 2019-09-17 CR CR20210175A patent/CR20210175A/es unknown
- 2019-09-17 WO PCT/US2019/051590 patent/WO2020061101A1/en not_active Ceased
- 2019-09-17 CN CN201980074583.3A patent/CN113227103B/zh active Active
-
2020
- 2020-05-12 US US15/930,309 patent/US10894797B2/en active Active
- 2020-09-18 US US17/025,790 patent/US11518772B2/en active Active
- 2020-10-19 US US17/074,337 patent/US11034705B2/en active Active
-
2021
- 2021-03-15 CL CL2021000628A patent/CL2021000628A1/es unknown
- 2021-03-17 SA SA521421505A patent/SA521421505B1/ar unknown
- 2021-03-17 PH PH12021550604A patent/PH12021550604A1/en unknown
- 2021-04-09 CO CONC2021/0004436A patent/CO2021004436A2/es unknown
-
2022
- 2022-11-01 US US18/051,679 patent/US12264167B2/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016203405A1 (en) * | 2015-06-19 | 2016-12-22 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
| WO2018013597A1 (en) * | 2016-07-12 | 2018-01-18 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN112996795B (zh) | 作为src同源-2磷酸酶抑制剂的稠合的三环衍生物 | |
| WO2023284730A1 (en) | Alkylidene derivatives as kras inhibitors | |
| WO2023249970A1 (en) | Bifunctional compounds containing pyrimidine derivatives for degrading cyclin-dependent kinase 2 via ubiquitin proteasome pathway | |
| CN119451967A (zh) | 用于经由泛素蛋白酶体途径降解细胞周期蛋白依赖性激酶2的含有吡啶并[2,3-d]嘧啶-7(8H)-酮衍生物的双功能化合物 | |
| CN119630651A (zh) | 用于经由泛素蛋白酶体途径降解细胞周期蛋白依赖性激酶2的含有经取代的嘧啶衍生物的双功能化合物 | |
| CN119790053A (zh) | 作为细胞周期蛋白依赖性激酶2抑制剂的磺酰胺衍生物 | |
| CN116783205A (zh) | 用于通过泛素蛋白酶体途径降解细胞周期蛋白依赖性激酶2的化合物 | |
| HK40064126A (en) | Fused tricyclic ring derivatives as src homology-2 phosphatase inhibitors | |
| HK40064126B (zh) | 作为src同源-2磷酸酶抑制剂的稠合的三环衍生物 | |
| HK40058474A (en) | Tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors | |
| HK40058474B (zh) | 作为src同源-2磷酸酶抑制剂的三取代的杂芳基衍生物 | |
| EA044940B1 (ru) | Производные конденсированного трициклического кольца в качестве ингибиторов фосфатазы с доменом гомологии src2 | |
| WO2026011344A1 (en) | Bifunctional compounds for degrading kras-12d via ubiquitin proteasome pathway |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 40064126 Country of ref document: HK |
|
| CB02 | Change of applicant information | ||
| CB02 | Change of applicant information |
Country or region after: U.S.A. Address after: Delaware, USA Applicant after: Nican therapy Address before: Delaware, USA Applicant before: Nikan medical Co. Country or region before: U.S.A. |
|
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Fu Jiping Inventor after: Lou Yan Inventor after: He Yigang Inventor before: J.Fu Inventor before: Y.Luo Inventor before: Y.He |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |